Study of DF6215 in Patients With Advanced Solid Tumors
Dragonfly Therapeutics
Dragonfly Therapeutics
Dana-Farber Cancer Institute
NeoImmuneTech
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
University of Pittsburgh
Merck Sharp & Dohme LLC
Tempest Therapeutics
Merck Sharp & Dohme LLC
Xencor, Inc.
Genexine, Inc.
Eisai Inc.
Yale University
M.D. Anderson Cancer Center
UNICANCER
RAPT Therapeutics, Inc.
Washington University School of Medicine
Sellas Life Sciences Group
Eli Lilly and Company
Astellas Pharma Inc
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute (NCI)
ImmunoGen, Inc.
Eli Lilly and Company
Celldex Therapeutics
UNICANCER
Medical College of Wisconsin
Duke University
Northwestern University
Corvus Pharmaceuticals, Inc.
University Medical Center Groningen
National Cancer Center Hospital East
Fate Therapeutics
Xencor, Inc.
Tesaro, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Dana-Farber Cancer Institute
University of Washington
Incyte Corporation
Merck Sharp & Dohme LLC
Cedars-Sinai Medical Center
Big Ten Cancer Research Consortium
Incyte Corporation
Roswell Park Cancer Institute
University Hospital, Ghent
Eisai Inc.